Earlier this year, India dealt some cards in Roche's ($RHHBY) favor when it suspended off-label eye sales of cancer drug Avastin on reports of vision problems in patients. The Swiss drugmaker has another much pricier option, Lucentis--which boasts a specific eye approval--that it would rather see used in that market. Now, though, India has lifted its alert on the advice of an expert committee, meaning Avastin is once again all clear for the sales. Story from FiercePharmaAsia | More